#Paris #France #Virbac #Supercharge #Thyronorm

Virbac Achieves Solid Growth in H1 2026

In a recent press release, Virbac, a leading player in the animal health market, showcased its remarkable performance during the first half of 2026. The company's revenue reached €768 million, marking an impressive 7.4% growth at constant exchange rates and scope (CERS), compared to the same period in 2025. This growth reflects strategic advancements in their product offerings, particularly the Supercharge platforms, which alone contributed double-digit growth to their financial results.

Financial Highlights

Virbac’s growth narrative is compelling, with actual rates showing a notable 4.0% increase, albeit impacted by unfavorable currency fluctuations. Revenue insights reveal a balanced performance across its segments, demonstrating a **+10.0% growth in companion animals and a 6.7% rise in farm animals. The success of the Supercharge platforms, particularly, underscores the potential harnessed from innovative product offerings, which delivered around 12% growth at CERS.

Further analysis into the volume/mix effects showcases a solid contribution of ~5.4%, complemented by a moderated price increase of ~2%. This strategic pricing, alongside increased volume sales, illustrates Virbac's effective management amidst challenging market conditions, particularly in North America.

Regional Performance

Regionally, North America held the spotlight, revealing robust double-digit growth. Despite temporary challenges related to toll manufacturing operations, the geographical diversity in performance remains a key strength for Virbac. Europe and international markets also demonstrated significant growth, recording increases of 6.5% and 7.5% respectively, at CERS.

The recent acquisition of Thyronorm has proven beneficial as well, contributing 1.4 percentage points to the overall growth in the first half, showcasing the strategic importance of acquisitions in bolstering Virbac's market presence and product lineup.

Paul Martingell, CEO of Virbac, expressed confidence in the company’s trajectory, stating: “In a challenging external environment, our performance in the first half of 2026 demonstrates both the robust fundamental demand across our portfolio and the expertise and dedication of our teams around the world.” Martingell further elaborated that achieving €768 million in revenue affirms Virbac’s positive direction, fortified by the strong performance across their core geographic areas and the effectiveness of their response to livestock health dynamics.

Future Outlook

Looking ahead, the company is optimistic about its growth trajectory, reaffirming its guidance for 2026 at the higher end of the initial revenue growth range between 5.5% and 7.5% at CERS, along with an adjusted recurring operating income margin targeting around 17%. The results of the first half have positioned Virbac favorably to reach these ambitious targets.

In conclusion, Virbac’s strategic focus on growth through its Supercharge platforms and careful management of acquisitions, alongside strong performances across diverse markets, highlights a successful strategy that could see further execution moving into the latter half of the year. The company remains a formidable player in the animal health industry, poised for continued success as it navigates a complex market landscape.